<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481884</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0827</org_study_id>
    <nct_id>NCT00481884</nct_id>
  </id_info>
  <brief_title>Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients</brief_title>
  <official_title>Phase III Trial to Compare RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine if RadiaPlexRx Hydrogel can reduce the development of grade 2 or higher&#xD;
      radiation dermatitis in breast cancer from adjuvant radiation when compared to a&#xD;
      petroleum-based gel (Aquaphor) commonly used as best supportive care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Gels:&#xD;
&#xD;
      RadiaPlexRx (requires a prescription) and Aquaphor (over-the-counter) are both gels that are&#xD;
      designed to treat irradiated (received radiation) breast skin.&#xD;
&#xD;
      These 2 gels contain different ingredients that may make one gel better than the other to&#xD;
      treat irradiated breast skin. RadiaPlexRx contains hyaluronic acid (an ingredient found&#xD;
      naturally in skin), aloe vera, and other ingredients that help the skin heal. Aquaphor is&#xD;
      made of mostly petroleum that helps protect the skin.&#xD;
&#xD;
      Application of Study Gels:&#xD;
&#xD;
      If you decide to participate in this study, the following steps will be taken:&#xD;
&#xD;
        -  You will be given detailed instructions on how to apply both of the gels. You should not&#xD;
           apply other gels or lotions on the areas of skin where you will be instructed to apply&#xD;
           the study gels, unless you are instructed to do so by the treating doctor.&#xD;
&#xD;
        -  You will receive a supply of both gels (in tubes) with enough to last for the length of&#xD;
           your treatment. You will know which gel is which, but each gel will be labeled with&#xD;
           &quot;outer&quot; or &quot;inner&quot; so that you will know which gel to use on which side. You should not&#xD;
           tell your treating doctor which side of the breast skin is being treated with which gel&#xD;
           so that a fair comparison of the gels can be made.&#xD;
&#xD;
        -  You will apply 1 gel to the outer side of the irradiated breast skin and the other gel&#xD;
           to the inner side of the irradiated breast skin.&#xD;
&#xD;
        -  If you experience any kind of allergic reaction (such as a rash) to the study gels, you&#xD;
           should notify the study doctor or study staff immediately.&#xD;
&#xD;
      Schedule for Study Gels:&#xD;
&#xD;
      You will need to follow the schedule for applying the gels as follows:&#xD;
&#xD;
        -  You will need to apply both gels starting 1 day before the start of radiation&#xD;
           treatments.&#xD;
&#xD;
        -  You will then need to apply both gels for 6 weeks during radiation treatment.&#xD;
&#xD;
        -  During the study period (1 day before the start of radiation treatment, during 6 weeks&#xD;
           of radiation treatment), you will need to apply both gels 3 times (in the morning,&#xD;
           afternoon, and evening just before going to sleep) each day at home.&#xD;
&#xD;
        -  During the days that you receive radiation treatment, you will be asked to apply the&#xD;
           gels immediately after you receive your radiation treatment. This will count as 1 of the&#xD;
           3 daily gel applications.&#xD;
&#xD;
      Clinic Visits:&#xD;
&#xD;
      You will have the following tests done during your clinic visits:&#xD;
&#xD;
        -  Three (3) sets of photos of your breast skin will be taken (before radiation starts and&#xD;
           during Weeks 3 and 6 of radiation therapy treatment).&#xD;
&#xD;
        -  During Weeks 1 through 6, you will go to the clinic to have your skin checked by your&#xD;
           treating physician to learn the effects of each gel on your symptoms. .&#xD;
&#xD;
        -  You will need to return any empty tubes of study gel so that new tubes can be given if&#xD;
           you will need more.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      If the treating doctor sees that the irradiated breast skin reacts poorly (does not improve&#xD;
      or gets worse) or you experience any intolerable side effects, you will be taken off this&#xD;
      study. Otherwise, the total time on this study is about 6 weeks.&#xD;
&#xD;
      End-of-Study:&#xD;
&#xD;
      -During your last week of radiation therapy treatment you will be asked to fill out a&#xD;
      questionnaire about how you felt about each gel.&#xD;
&#xD;
      This is an investigational study. RadiaPlexRx and Aquaphor are both FDA approved and&#xD;
      commercially available. Up to 92 patients will take part in this study. All will be enrolled&#xD;
      at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients using RadiaPlexRx Hydrogel that developed grade 2 or higher radiation dermatitis in breast cancer from adjuvant radiation compared to a petroleum-based gel (Aquaphor) commonly used as best supportive care</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Radiation Dermatitis</condition>
  <arm_group>
    <arm_group_label>RadiaPlexRx Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aquaphor Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RadiaPlexRx Gel</intervention_name>
    <description>RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.</description>
    <arm_group_label>RadiaPlexRx Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aquaphor Gel</intervention_name>
    <description>Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.</description>
    <arm_group_label>Aquaphor Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has histologically-confirmed carcinoma of breast (all subtypes are permitted)&#xD;
&#xD;
          2. Patient has breast conserving surgery (lumpectomy) for breast cancer with negative&#xD;
             surgical margin&#xD;
&#xD;
          3. Stage Tis,0-3 N0-2 M0&#xD;
&#xD;
          4. Patient will receive irradiation of whole breast. An additional field to treat the&#xD;
             supraclavicular / axillary apex lymphatics is allowed, but a separate field to treat&#xD;
             the internal mammary chain nodes is not allowed&#xD;
&#xD;
          5. The breast will receive radiation dose greater than or equal to 50 Gy, with or without&#xD;
             a boost field to give additional dose to the tumor bed&#xD;
&#xD;
          6. Patient wears bras with cup size larger than A&#xD;
&#xD;
          7. Patient signs informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Breast cancer treatment with mastectomy&#xD;
&#xD;
          2. Stage T4 breast cancer&#xD;
&#xD;
          3. Patient will require the use of tissue-equivalent bolus during radiation treatment or&#xD;
             double treatment of junctions of radiation treatment fields&#xD;
&#xD;
          4. Patient will require treatment to the internal mammary chain lymph node bed using a&#xD;
             separate radiation electron field&#xD;
&#xD;
          5. Patient is planned for partial-breast irradiation or Mammo-site treatment.&#xD;
&#xD;
          6. Patient has unhealed wound or rash in the radiation field&#xD;
&#xD;
          7. Patient has allergy to RadiaPlexRx or aloe vera&#xD;
&#xD;
          8. Patient has systemic lupus erythematosus or scleroderma that increases the risk of&#xD;
             radiation dermatitis development&#xD;
&#xD;
          9. Patient will receive concurrent chemotherapy with radiation. (Patient is allowed to&#xD;
             take concurrent hormonal therapy or HerceptinÂ® [Trastuzumab])&#xD;
&#xD;
         10. Planned accelerated fractionation.&#xD;
&#xD;
         11. Planned radiation therapy to the bilateral breasts&#xD;
&#xD;
         12. Planned breast irradiation in the prone position&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Buchholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Radiation Dermatitis</keyword>
  <keyword>RadiaPlexRx Gel</keyword>
  <keyword>Aquaphor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

